Showing results (61-70 of 217) with videos related to

Sort By:
Pageof 22
Anticancer Research|March 6, 2020
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial CarcinomaMasahiro Ogawa, Shinya Yamamoto, Toru Inoue, et al.
Anticancer Research|March 29, 2022
Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted TherapyMotohiro Fujiwara, Ryo Fujiwara, Tomohiko Oguchi, et al.
International Cancer Conference Journal|June 1, 2019
A case of gastric metastasis from renal cell cancer during the sequential targeted therapySho Uehara, Takeshi Yuasa, Junko Fujisaki, et al.
The Annals of Thoracic Surgery|January 23, 2003
Direct compression of the failing heart reestablishes maximal mechanical efficiencyRussell A J Carrington, Yifei Huang, Osamu Kawaguchi, et al.
International Journal of Hematology|February 26, 2004
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell linesShinya Kimura, Junya Kuroda, Hidekazu Segawa, et al.
Japanese Journal of Clinical Oncology|October 24, 2021
Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer: a single-institutional studyKazuma Sasamura, Takashi Soyano, Takuyo Kozuka, et al.
Advances in Radiation Oncology|December 22, 2021
Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After ProstatectomyNana Shimoyachi, Yasuo Yoshioka, Kazuma Sasamura, et al.
Oncology Research|April 21, 2005
Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cellsMasaki Nogawa, Takeshi Yuasa, Shinya Kimura, et al.
Anticancer Research|July 3, 2019
Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial CancerShotaro Yasuoka, Takeshi Yuasa, Noriko Nishimura, et al.
Anticancer Research|March 29, 2022
Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial CancerMotohiro Fujiwara, Ryo Fujiwara, Tetsuya Urasaki, et al.
Pageof 22